NO972623L - Farmasöytisk blanding omfattende lamotrigin - Google Patents

Farmasöytisk blanding omfattende lamotrigin

Info

Publication number
NO972623L
NO972623L NO972623A NO972623A NO972623L NO 972623 L NO972623 L NO 972623L NO 972623 A NO972623 A NO 972623A NO 972623 A NO972623 A NO 972623A NO 972623 L NO972623 L NO 972623L
Authority
NO
Norway
Prior art keywords
weight
granules
lamotrigine
pharmaceutical composition
particle size
Prior art date
Application number
NO972623A
Other languages
English (en)
Norwegian (no)
Other versions
NO972623D0 (no
Inventor
Simon Philip Hiskett
Susan Ann Taylor
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO972623D0 publication Critical patent/NO972623D0/no
Publication of NO972623L publication Critical patent/NO972623L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
NO972623A 1994-12-07 1997-06-06 Farmasöytisk blanding omfattende lamotrigin NO972623L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (2)

Publication Number Publication Date
NO972623D0 NO972623D0 (no) 1997-06-06
NO972623L true NO972623L (no) 1997-08-06

Family

ID=10765604

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972623A NO972623L (no) 1994-12-07 1997-06-06 Farmasöytisk blanding omfattende lamotrigin

Country Status (19)

Country Link
US (1) US5861179A (de)
EP (1) EP0797441B1 (de)
JP (1) JP2977284B2 (de)
CN (1) CN1174505A (de)
AT (1) ATE213633T1 (de)
AU (1) AU696406B2 (de)
BR (1) BR9509975A (de)
CA (1) CA2207284A1 (de)
CZ (1) CZ171797A3 (de)
DE (1) DE69525649T2 (de)
ES (1) ES2172600T3 (de)
FI (1) FI972434A7 (de)
GB (1) GB9424766D0 (de)
HU (1) HUT77367A (de)
NO (1) NO972623L (de)
NZ (1) NZ296573A (de)
PL (1) PL320560A1 (de)
RU (1) RU2160106C2 (de)
WO (1) WO1996017611A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
AU1970797A (en) * 1997-02-25 1998-09-09 Procter & Gamble Company, The Wet granulating method
EP1098636A1 (de) * 1998-07-23 2001-05-16 Novo Nordisk A/S Feuchtgranulierungstechnik zur zubereitung einer stabilen parmazeutischen zusammensetzung
WO2000078907A1 (en) * 1999-06-21 2000-12-28 The Procter & Gamble Company Processes for making granular detergent in a fluidized bed granulator having recycling of improperly sized particles
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
CA2483103A1 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1608342A2 (de) * 2003-03-21 2005-12-28 Ranbaxy Laboratories, Ltd. Stabile arzneizusammensetzungen mit lamotrigine und deren herstellungsverfahren
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
EP1663182B2 (de) 2003-09-12 2019-11-20 Amgen Inc. SCHNELL AUFLÖSENDE FORMULIERUNG VON CINACALCET HCl
US20070225727A1 (en) * 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
WO2008104996A2 (en) * 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US20130108697A1 (en) 2010-03-04 2013-05-02 Ramakant Kashinath Gundo Modified release dosage form
WO2018071547A1 (en) * 2016-10-11 2018-04-19 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
AR227521A1 (es) * 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
DE69016283T3 (de) * 1989-06-30 1998-04-02 Sumitomo Electric Industries Substrat mit einer supraleitenden Schicht.
GB2278057B (en) * 1991-01-30 1995-02-01 Wellcome Found Water-dispersible tablets containing lamotrigine
AU653203B2 (en) * 1991-01-30 1994-09-22 Wellcome Foundation Limited, The Water-dispersible tablets
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) * 1993-01-07 1994-07-08 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets

Also Published As

Publication number Publication date
NO972623D0 (no) 1997-06-06
JPH10510255A (ja) 1998-10-06
WO1996017611A1 (en) 1996-06-13
ATE213633T1 (de) 2002-03-15
CZ171797A3 (en) 1997-11-12
PL320560A1 (en) 1997-10-13
FI972434L (fi) 1997-06-09
RU2160106C2 (ru) 2000-12-10
NZ296573A (en) 1997-08-22
DE69525649T2 (de) 2002-09-05
FI972434A0 (fi) 1997-06-06
AU696406B2 (en) 1998-09-10
FI972434A7 (fi) 1997-06-09
US5861179A (en) 1999-01-19
EP0797441A1 (de) 1997-10-01
CN1174505A (zh) 1998-02-25
MX9704103A (es) 1997-09-30
DE69525649D1 (de) 2002-04-04
EP0797441B1 (de) 2002-02-27
GB9424766D0 (en) 1995-02-08
JP2977284B2 (ja) 1999-11-15
BR9509975A (pt) 1998-06-09
HUT77367A (hu) 1998-03-30
CA2207284A1 (en) 1996-06-13
ES2172600T3 (es) 2002-10-01
AU4121196A (en) 1996-06-26

Similar Documents

Publication Publication Date Title
NO972623L (no) Farmasöytisk blanding omfattende lamotrigin
AU724946B2 (en) Tablets containing beta-lactam antibiotic and process for producing the same
DE69212608T2 (de) Arzneimittel enthaltend oral absorbierbare Glycosaminoglycane
DE69104453T2 (de) Stabilisierte feste chemische Zusammensetzungen.
AU7407387A (en) Controlled release dihydrocodeine composition
DE69916522T2 (de) Verfahren zur Herstellung wasserdispergierbare Sterol Formulierungen
SA98190095B1 (ar) تركيبة صيدلانية لتعاطى n- piperidino-5-(4-cholorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide واملاحها ومنحلاتها
CA2121435A1 (en) Aqueous pharmaceutical suspension and process for preparation thereof
US5968553A (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
EE03039B1 (et) Meetod hüdrateeritud tsefalosporiini kuiva pulbrilise segu valmistamiseks, sellel meetodil valmistatud segu ja farmatseutilised kompositsioonid
CA2330480A1 (en) Controlled release formulation of divalproex sodium
SA95160013B1 (ar) تكوين حبيبات رطبة لأحماض bisphosphonic
HU229936B1 (en) Particles coated with granulated crystalline ibuprofen
US5460829A (en) Pharmaceutical compositions based on ebastine or analogues thereof
ZA200309289B (en) Oxcarbazepine dosage forms.
AU742382B2 (en) Pharmaceutical preparation containing levothyroxine sodium
SK119799A3 (en) Swallow tablet comprising paracetamol
RU97111870A (ru) Фармацевтический состав, содержащий ламотригин
Wintersberger DNA-dependent RNA polymerase from mitochondria of a cytoplasmic “petite” mutant of yeast
FI944182A0 (fi) Yhtenäiskiteitä sisältävä koostumus, menetelmä senYhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö valmistamiseksi ja sen käyttö
PL177607B1 (pl) Tabletka o opóźnionym uwalnianiu zawierająca sól sodową diklofenaku
Vree et al. Pharmacokinetics and mechanism of renal excretion of short acting sulphonamides and N4-acetylsulphonamide derivatives in man: Structural requirements of sulphonamides for active tubular secretion
PT95304A (pt) Processo para a preparacao de uma composicao de acetominofeno
US4536511A (en) Medicaments containing muzolimine, their use and processes for their production
US5432166A (en) Use of 1-(β-D-arabinofuranosyl) -5-propynyluracil for lowering serum cholesterol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application